Innoviva, Inc. (INVA) Stock
INVA has an Alpha Score of 74 out of 100 (moderate), computed on Oct 29, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 2 trades in INVA since 2025: 0 purchases and 2 sales, most recently George Whitesides (sale, Mar 25, 2025). 6 of the hedge funds AlphaScala tracks reported INVA in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $91.67M. Its trailing P/E ratio is 4.3 and its net margin 81.2% (key statistics as of Oct 23, 2026).
What is INVA's Alpha Score?
How it works →Alpha Score of 74 reflects strong overall profile with moderate momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 29, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Innoviva, Inc. (INVA)?
Most recent: George Whitesides (sale, Mar 25, 2025); records start Mar 24, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| George Whitesides D-CA · House | 2025-03-25 | sale | $250k – $500k |
| George Whitesides D-CA · House | 2025-03-24 | sale | $50k – $100k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all INVA political trades →Which hedge funds own INVA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 4.04M | $91.67M | -0% |
| Millennium Management Israel Englander | 2.54M | $57.71M | +11% |
| Marshall Wace | 1.45M | $33.03M | -3% |
| Citadel Ken Griffin | 186K | $4.22M | +5% |
| D.E. Shaw David Shaw | 166K | $3.78M | -33% |
| Hussman Investment Trust John Hussman | 105K | $2.23M | n/a |
13F holdings as of Sep 30, 2026
Explore all tracked funds →What are INVA's key statistics?
Key statistics as of Oct 23, 2026
How does INVA's valuation compare with the Healthcare sector?
| Metric | INVA | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 4.3 | 27.0 | 102 |
| Net margin | 81.19% | 4.64% | 150 |
| Return on equity | 30.03% | 6.41% | 169 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
INVA price chart
Powered by TradingViewWhat does Innoviva, Inc. do?
Innoviva Inc. is an innovative pharmaceutical company, focusing primarily on managing royalty portfolios that originate from collaborations with external partners. This asset plays a significant role in the healthcare sector, specifically within the pharmaceuticals and biotechnology industries. The company is involved in the development and commercialization of products in the respiratory disease space, notably co-developing medicines that address chronic obstructive pulmonary disease (COPD) and asthma. Innoviva Inc.'s strategy revolves around optimizing the value of its intellectual property through strategic partnerships with major pharmaceutical players. By leveraging its royalty agreements, the company aims to maximize returns while minimizing direct operational risks associated with drug development. Founded in 1996 as Theravance, the firm transitioned to Innoviva Inc., illustrating a shift towards focusing on royalty management and investment in biopharmaceutical innovations. This positioning allows Innoviva to have a significant presence in the market, impacting the treatment approaches in the respiratory disease segment and contributing to the broader pharmaceutical and healthcare ecosystem."}